MRP1 expression in CTCs confers resistance to irinotecan-based chemotherapy in metastatic colorectal cancer
Emne Ali Abdallah, Marcello Ferretti Fanelli, Virgílio Souza E Silva, Marcelo Calil Machado Netto, José Luiz Gasparini Junior, Daniel Vilarim Araújo, Luciana Menezes Mendonça Ocea, Marcilei Eliza Cavicchioli Buim, Milena Shizue Tariki, Vanessa da Silva Alves, Victor Piana de Andrade, Aldo Lourenço Abbade Dettino, Celso Abdon Lopes de Mello, Ludmilla Thomé Domingos Chinen, Emne Ali Abdallah, Marcello Ferretti Fanelli, Virgílio Souza E Silva, Marcelo Calil Machado Netto, José Luiz Gasparini Junior, Daniel Vilarim Araújo, Luciana Menezes Mendonça Ocea, Marcilei Eliza Cavicchioli Buim, Milena Shizue Tariki, Vanessa da Silva Alves, Victor Piana de Andrade, Aldo Lourenço Abbade Dettino, Celso Abdon Lopes de Mello, Ludmilla Thomé Domingos Chinen
Abstract
Circulating tumor cells are important markers of tumor progression and can reflect tumor behavior in metastatic colorectal cancer (mCRC). Identification of proteins that confer resistance to treatment is an important step to predict response and better selection of treatment for patients. Multidrug resistance-associated protein 1 (MRP1) and Multidrug resistance-associated protein 4 (MRP4) play a role in irinotecan-resistance, and Excision Repair Cross-Complementation group 1 (ERCC1) expression can confer resistance to platinum compounds. Here, we included 34 patients with mCRC and most of them received FOLFIRI or FOLFOX chemotherapy (91.1%). CTCs were isolated by ISET(®) Technology and identified in 30 patients (88.2%), with a median of 2.0 CTCs/mL (0-31.0). We analyzed the immunocytochemical expression of MRP1, MRP4 and ERCC1 only in patients who had previously detectable CTCs, accordingly to treatment received (n = 19, 15 and 13 patients, respectively). Among patients treated with irinotecan-based chemotherapy, 4 out of 19 cases with MRP1 positive CTCs showed a worse progression free survival (PFS) in comparison to those with MRP1 negative CTCs (2.1 months vs. 9.1 months; p = 0.003). None of the other proteins studied in CTCs had significant association with PFS. We analyzed also histological sections of primary tumors and metastases by immunohistochemistry, and found no association with clinicopathological characteristics or with PFS. Our results show MRP1 as a potential biomarker of resistance to treatment with irinotecan when found in CTCs from mCRC patients. This is a small proof-of-principle study and these early findings need to be validated in a larger cohort of patients.
Keywords: ISET; chemoresistance; circulating tumor cells; metastatic colorectal cancer; multidrug resistance-associated protein 1.
© 2016 UICC.
Source: PubMed